小智港股覆盤 | 2月9日
今日，港股三大指數集體上漲。截止收盤，恆生指數大漲2.06%，報24829點。國企指數大漲2.47%，報8723點。恆生科技指數大漲3.65%，報5635點。市場約1077只個股上漲，660只個股下跌。成交額突破1407.58億港幣，和昨天同期相比增長8.68%。南下資金淨流入27.4億港幣。
盤面上，建築建材板塊全線走強。中國建築興業漲超8%；中國聯塑漲超6%；中國玻璃漲超4%；洛陽玻璃股份漲超1%。
有色金屬和鋼鐵板塊暴漲。俄鋁漲超10%；中國鋁業漲超9%；紫金礦業、星宇控股等多股漲超7%；中國宏橋漲超5%。俄鋁全年鋁產量共376.4萬噸，同比升0.2%；麥格理：資源股首選中國鋁業及福耀玻璃等。
電商板塊全線走強。阿裏巴巴-SW漲超6%；京東集團-SW漲超4%；攜程集團-S、美團-W、寶尊電商-SW等多股漲超3%。阿裏巴巴-SW反彈6%，孫正義強調軟銀仍然長期持有阿裏股份；(2月7日)油價創七年新高，春節期間攜程訂單量同比增長30%。
CRO板塊走弱。方達控股跌超8%；康龍化成跌超5%；藥明康德跌超4%；中國醫療集團跌超3%；泰格醫藥跌超1%。方達控股獲主席李鬆增持150萬股；康龍化成股東信中康成通過大宗交易減持約70.76萬股；藥明康德稱未被美列入未經覈實名單，無持有藥明生物股份。
生物科技板塊走弱。和譽-B跌超12%；中國再生醫學跌超8%；歌禮制藥-B跌超7%；亞盛醫藥-B、中國抗體-B等多股跌超5%。和譽-B:完成口服抑制劑ABSK011與atezolizumab聯合用藥臨牀II期首例患者給藥；歌禮制藥-B高開逾7%，自主研發的抗病毒口服藥物ASC10在臨牀試驗中對新冠肺炎的療效可能比莫努匹韋更好；中國抗體-B：SN1011新藥研究申請獲國家藥監局藥品審評中心受理。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
